sj-pdf-3-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial

Autor:	Klein, Brad C, Miceli, Rosa, Severt, Lawrence, McAllister, Peter, Mechtler, Laszlo, McVige, Jennifer, Diamond, Merle, Marmura, Michael J, Guo, Hua, Finnegan, Michelle, Trugman, Joel M
Rok vydání:	2023
Předmět:	FOS: Psychology FOS: Clinical medicine 170199 Psychology not elsewhere classified 110319 Psychiatry (incl. Psychotherapy) 110306 Endocrinology 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified 110904 Neurology and Neuromuscular Diseases Neuroscience
ISSN:	0333-1024
DOI:	10.25384/sage.21845327.v1
Popis:	Supplemental material, sj-pdf-3-cep-10.1177_03331024221128250 for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial by Brad C Klein, Rosa Miceli, Lawrence Severt, Peter McAllister, Laszlo Mechtler, Jennifer McVige, Merle Diamond, Michael J Marmura, Hua Guo, Michelle Finnegan and Joel M Trugman in Cephalalgia
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::11d3983c1578bcc40c1d880eca32d6f1 Zobrazit plný text záznamu